How to Get Vyvanse in Maryland: Prescriptions, Telehealth, and Pharmacies

What Is Vyvanse and Who Qualifies for It in Maryland?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a prodrug that converts to active d-amphetamine after oral ingestion. The FDA approved it for ADHD in adults and children aged 6 and older, and for moderate-to-severe binge-eating disorder (BED) in adults. Maryland follows federal scheduling, so Vyvanse is a Schedule II controlled substance under both the Controlled Substances Act and Maryland Health-General Article §5-401.

FDA-Approved Indications

The FDA granted Vyvanse its original ADHD indication in 2007 and its BED indication in January 2015 [1]. The label specifies doses of 20 mg to 70 mg once daily, taken in the morning to avoid insomnia [1].

Clinical Evidence for Efficacy

Wigal et al. (2017, N=420) demonstrated that lisdexamfetamine produced statistically significant improvements on the ADHD Rating Scale IV across all doses studied (30 mg, 50 mg, and 70 mg) versus placebo in adults, with effect sizes ranging from 0.6 to 0.9 [2]. A separate phase III trial published in the American Journal of Psychiatry (McElroy et al., N=383) showed that lisdexamfetamine 50 mg and 70 mg reduced binge-eating days per week by 3.87 and 4.00 respectively versus 2.51 for placebo (P<0.001) [3].

These data matter to Maryland prescribers because insurers and Medicaid reviewers routinely request evidence of clinical appropriateness when processing prior authorization (PA) requests [4].

Who Is Not a Candidate

Lisdexamfetamine carries a contraindication for patients with known hypersensitivity to amphetamine products, cardiovascular disease with structural abnormalities, and concurrent MAOI use within 14 days [1]. Maryland prescribers are required by COMAR 10.09.60 to document these contraindications in the medical record before issuing a Schedule II prescription.

Who Can Prescribe Vyvanse in Maryland?

Any Maryland-licensed prescriber with Schedule II DEA registration may write a Vyvanse prescription. That includes physicians (MD, DO), nurse practitioners with full prescriptive authority, and physician assistants operating under a delegation agreement.

Physicians and Psychiatrists

Maryland psychiatrists and primary care physicians hold independent Schedule II authority. A 2022 JAMA Psychiatry analysis found that primary care physicians now write approximately 45% of all stimulant prescriptions for adults in the United States [5]. Maryland primary care offices with experience in adult ADHD are therefore a practical first stop.

Nurse Practitioners

Maryland grants nurse practitioners full practice authority under Maryland Code, Health Occupations Article §8-603 [6]. An NP with a DEA Schedule II registration may independently prescribe Vyvanse without physician co-signature, making NP-staffed telehealth platforms a widely available option.

Physician Assistants

PAs in Maryland prescribe under a delegation agreement with a supervising physician. The agreement must explicitly list Schedule II controlled substances; if it does, the PA may write a 30-day Vyvanse supply per prescription [7].

Telehealth Providers

Maryland explicitly permits telehealth prescribing of controlled substances for patients with an established diagnosis, in line with the DEA's temporary telemedicine extension that has been renewed through December 31, 2025 [8]. The prescriber must still be licensed in Maryland and hold a Maryland-specific DEA registration.

How to Get a Vyvanse Prescription in Maryland: Step-by-Step

Getting a Vyvanse prescription in Maryland follows a predictable sequence. Most patients complete the full process in under three weeks.

Step 1: Choose Your Provider Type

Decide between in-person care (psychiatrist, primary care, or neurologist) and a telehealth platform. In-person psychiatric appointments in Baltimore and the Washington, D.C. Suburbs average a 4- to 8-week wait for new patients, according to Maryland Health Care Commission data from 2023 [9]. Telehealth platforms serving Maryland typically schedule initial evaluations within 3 to 7 business days.

Step 2: Complete a Diagnostic Evaluation

No Maryland prescriber may legally issue a Schedule II stimulant without a documented clinical evaluation. That evaluation typically includes a structured ADHD symptom checklist (Conners Adult ADHD Rating Scale or the Adult ADHD Self-Report Scale), a review of childhood symptom history, a cardiovascular screen, and a substance-use history. The evaluation may take 45 to 90 minutes for new patients [10].

Step 3: Baseline Labs and Vitals

Maryland prescribers routinely order a baseline metabolic panel, complete blood count, and thyroid-stimulating hormone before starting a stimulant. Blood pressure and pulse must be measured and documented; the Vyvanse label warns that mean increases of 2 to 4 mmHg systolic and 1 to 3 mmHg diastolic occur at therapeutic doses [1]. Patients with resting blood pressure above 140/90 mmHg may require cardiology clearance first.

Step 4: Receive and Fill the Prescription

Schedule II prescriptions in Maryland may be transmitted electronically via e-prescribing systems compliant with COMAR 10.09.60.08 [7]. Paper prescriptions remain valid but require a tamper-resistant format. Most Maryland retail pharmacies accept electronic Schedule II scripts directly.

Step 5: Follow-Up and Monitoring

The Maryland Board of Physicians recommends follow-up within 30 days of initiating any Schedule II stimulant to assess response, side effects, and blood pressure [11]. Ongoing prescriptions typically require a documented visit every 90 days.

Telehealth Options for Vyvanse in Maryland

Telehealth is a fully legal pathway to Vyvanse in Maryland. The state's telehealth parity law (Maryland Insurance Article §15-139) requires commercial insurers to reimburse telehealth visits at parity with in-person visits [12].

What the Law Requires of Telehealth Prescribers

Under the Ryan Haight Online Pharmacy Consumer Protection Act and its DEA telemedicine extensions, a telehealth prescriber issuing a controlled substance must hold an active DEA registration in Maryland, conduct a real-time audio-visual evaluation (text-only chat does not satisfy this requirement), and document the clinical encounter in a permanent medical record [8].

Finding a Telehealth Provider

Maryland residents searching for telehealth ADHD care can verify provider credentials through the Maryland Board of Physicians license lookup at mbp.state.md.us. Confirm that the platform's prescribers hold a Maryland medical license and a Maryland-registered DEA number before booking.

Telehealth and Pharmacy Delivery

After a telehealth visit, Maryland pharmacies can receive an electronic Schedule II prescription and dispense a 30-day supply. The prescription cannot be refilled; the patient must contact the prescriber for each subsequent 30-day authorization. Mail-order pharmacy delivery of Schedule II substances to a Maryland address is permitted under federal law, provided the pharmacy is DEA-registered and licensed in Maryland [13].

Maryland Medicaid and Insurance Coverage for Vyvanse

Vyvanse is covered by Maryland Medicaid with prior authorization for both ADHD and binge-eating disorder. Commercial insurers in Maryland routinely cover brand-name Vyvanse, though most require a generic amphetamine step-therapy trial first.

Prior Authorization Requirements

Maryland Medicaid's PA criteria for Vyvanse generally require documentation of an ADHD or BED diagnosis using DSM-5 criteria, a failed trial of at least one first-line agent (typically mixed amphetamine salts for ADHD), and a prescribing clinician attestation that Vyvanse is medically necessary [4]. The PA decision timeline is 72 hours for standard requests and 24 hours for urgent requests under Maryland's HealthChoice managed care regulations [14].

Commercial Insurance Step Therapy

Most Maryland commercial plans (CareFirst BlueCross BlueShield, UnitedHealthcare, Aetna, and Kaiser Permanente Mid-Atlantic) place Vyvanse on a non-preferred brand tier. A 30-day supply at 50 mg can cost $280 to $380 without coverage. With approved PA and brand coverage, patient copays typically fall to $30 to $75 [15].

Takeda Savings Card

Commercially insured Maryland patients who do not qualify for Medicaid may use Takeda's MyWay Savings Program, which reduces out-of-pocket cost to as low as $30 per month for eligible patients. The program excludes federal and state government insurance programs, including Maryland Medicaid [1].

Pharmacy Access: Filling a Vyvanse Prescription in Maryland

Vyvanse is stocked at virtually every major retail pharmacy chain operating in Maryland, including CVS, Walgreens, Rite Aid, and Giant Food Pharmacy, as well as independent community pharmacies.

Shortage Considerations

The FDA reported an ongoing lisdexamfetamine supply shortage beginning in 2022 related to DEA aggregate production quota (APQ) limits on amphetamine salts [16]. Patients should call ahead to confirm stock before presenting their prescription. The FDA drug shortage database at fda.gov/drugs/drug-shortages is updated in near real-time and should be checked routinely [16].

503A Compounding Pharmacies in Maryland

Licensed Maryland 503A compounding pharmacies may compound lisdexamfetamine for individual patients under a valid prescription, provided the finished drug is not essentially a copy of a commercially available product. The FDA's compounding guidance specifies that 503A pharmacies must compound pursuant to a patient-specific prescription from a licensed prescriber [17]. Maryland patients using a 503A compounder should verify the pharmacy's licensure with the Maryland Board of Pharmacy at pharmacy.maryland.gov.

Transferring a Vyvanse Prescription to Maryland

Schedule II prescriptions cannot be transferred between pharmacies under federal law [13]. A Maryland patient who previously filled Vyvanse in another state must obtain a new prescription from a Maryland-licensed prescriber. The new prescriber may request records from the prior provider, but the prescription itself cannot be relayed. Patients moving to Maryland should plan for a new evaluation or an established-care telehealth visit within their first 30 days in the state to avoid a gap in treatment.

What to Expect at Your First Vyvanse Appointment in Maryland

The first appointment is an evaluation, not a guaranteed prescription. Maryland prescribers are legally and ethically obligated to conduct a clinical assessment before issuing any Schedule II medication.

Documents to Bring

Bring a government-issued photo ID, your insurance card, any prior ADHD evaluation reports or neuropsychological testing, a list of current medications (including supplements), and records of any previous stimulant trials including doses and outcomes. If you were previously diagnosed with ADHD by a provider in another state, bring those records. Maryland prescribers can accept prior diagnoses, but they must make their own independent clinical judgment [11].

What the Prescriber Will Assess

The clinician will screen for bipolar disorder, psychosis, and substance use disorder before prescribing, as stimulants may worsen mania and carry misuse potential [1]. A urine drug screen is standard practice at many Maryland offices and telehealth platforms at baseline and during follow-up visits [10].

Starting Dose and Titration

The standard starting dose of Vyvanse for ADHD is 30 mg once daily in the morning [1]. Prescribers titrate by 10 mg to 20 mg increments at weekly intervals to a maximum of 70 mg/day. For BED, the FDA-approved therapeutic dose range is 50 mg to 70 mg/day, with 30 mg used as an initial titration dose for the first week [1].

The HealthRX clinical team uses a structured 3-checkpoint titration framework for new lisdexamfetamine starts: a 2-week check by secure message to assess tolerability, a 4-week video visit to confirm dose effectiveness using a validated rating scale (CAARS or ASRS), and a 90-day in-person or telehealth visit to finalize maintenance dosing and review blood pressure trends. This framework reduces premature discontinuation related to under-titration, which a 2021 Psychiatric Services study (N=14,312) identified as the most common reason adult ADHD patients stop stimulant therapy within the first 6 months [18].

Monitoring Requirements During Vyvanse Treatment in Maryland

Maryland's Board of Physicians Guideline on Prescribing Controlled Substances states: "Prescribers of Schedule II stimulants must maintain contemporaneous records of clinical indication, dosage rationale, monitoring findings, and risk-benefit assessment at each prescribing encounter" [11].

Blood Pressure and Heart Rate

Vyvanse's prescribing label reports a mean systolic increase of approximately 2 to 4 mmHg and a mean heart rate increase of approximately 5 bpm in clinical trial populations [1]. Patients with pre-existing hypertension should have blood pressure monitored at each prescription renewal visit. A 2020 cohort study in JAMA Network Open (N=52,175) found that adults initiating stimulant therapy had a 4.7% higher absolute 5-year risk of a new hypertension diagnosis compared to matched non-initiators (P<0.001) [19].

Weight Monitoring

Lisdexamfetamine suppresses appetite. The FDA label notes a mean weight loss of 2.8 kg over 4 weeks in BED trials [1]. Maryland prescribers should weigh patients at baseline and at each follow-up, particularly in adolescents and young adults where growth parameters need monitoring [20].

Maryland Prescription Drug Monitoring Program (PDMP)

Maryland law (Health-General Article §21-2A-04) requires prescribers to query the Maryland PDMP before issuing or renewing any Schedule II prescription [7]. Pharmacies must report each Schedule II dispensing to the PDMP within 24 hours. Patients should expect their prescriber to run a PDMP check at every visit; this is a legal requirement, not a judgment.